Professor Emeritus Herb Boyer's discovery of recombinant DNA changed medicine, ushering in a new era in biological treatments ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the South San Francisco-based genetic testing company filed for Chapter 11 bankruptcy protection.

In trading on Friday, biotechnology shares were relative leaders, up on the day by about 2.5%. Leading the group were shares of Inozyme Pharma, up about 177.5% and shares of Emergent BioSolutions ...

Investors in these stocks should be very aware that early-stage biotech stocks have huge upside but also bust potential, and to invest within your risk tolerance accordingly. Billy Duberstein and ...